Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER

NCT ID: NCT03068130

Last Updated: 2025-06-11

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

261 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-18

Study Completion Date

2020-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with pulmonary hypertension (PH) who previously participated in controlled clinical studies with bardoxolone methyl.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with pulmonary hypertension (PH) who previously participated in controlled clinical studies with bardoxolone methyl.

Qualified patients will receive 10 mg of bardoxolone methyl once daily until the drug is available through commercial channels or until patient withdrawal, whichever is sooner. Dose de-escalation (down to 5 mg) is permitted during the study, if indicated clinically.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bardoxolone methyl 10 mg

Bardoxolone methyl will be administered orally once daily at 10 mg until it becomes commercially available. Dose de-escalation (down to 5 mg) is permitted during the study, if indicated clinically.

Group Type EXPERIMENTAL

Bardoxolone methyl

Intervention Type DRUG

Capsules of Bardoxolone methyl

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bardoxolone methyl

Capsules of Bardoxolone methyl

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RTA 402

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Treatment-compliant patients who are participating in qualifying ongoing studies and have completed required End-of-Treatment and/or Follow-up visits in a prior clinical study with bardoxolone methyl

Exclusion Criteria

* Participation in other investigational clinical studies involving interventional products being tested or used in a way different from the approved form or when used for an unapproved indication;
* Patients who have an ongoing SAE from a clinical study that is assessed by the investigator as related to bardoxolone methyl;
* Unwilling to practice acceptable methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) while taking study drug;
* Women who are pregnant or breastfeeding;
* Patient is, in the opinion of the investigator, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason;
* Known hypersensitivity to any component of the study drug
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biogen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Banner University Medical Center, Phoenix Advanced Lung Disease Institute

Phoenix, Arizona, United States

Site Status

Arizona Pulmonary Specialists

Phoenix, Arizona, United States

Site Status

Cedars Sinai Medical Center

Beverly Hills, California, United States

Site Status

University of California San Diego

La Jolla, California, United States

Site Status

VA Healthcare System of Greater Los Angeles

Los Angeles, California, United States

Site Status

David Geffen School of Medicine UCLA

Los Angeles, California, United States

Site Status

University of California Davis Medical Center - Division of Pulmonary and Critical Care

Sacramento, California, United States

Site Status

Harbor - UCLA Medical Center

Torrance, California, United States

Site Status

University of Colorado Denver - Division of Pulmonary Sciences

Aurora, Colorado, United States

Site Status

Georgetown University Medical Center - Department of Rheumatology

Washington D.C., District of Columbia, United States

Site Status

University of Miami Miller School of Medicine

Miami, Florida, United States

Site Status

Cleveland Clinic of Florida

Weston, Florida, United States

Site Status

Augusta University

Augusta, Georgia, United States

Site Status

Piedmont-Georgia Lung

Austell, Georgia, United States

Site Status

Northwestern Memorial Hospital

Chicago, Illinois, United States

Site Status

University of Illinois at Chicago

Chicago, Illinois, United States

Site Status

University of Chicago

Chicago, Illinois, United States

Site Status

Kentuckiana Pulmonary Associates

Louisville, Kentucky, United States

Site Status

Maine Medical Center - Division of Pulmonary and Critical Care Medicine

Portland, Maine, United States

Site Status

Tufts Medical Center

Boston, Massachusetts, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Brigham and Women's Hospital

Boston, Massachusetts, United States

Site Status

Boston University School of Medicine

Boston, Massachusetts, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

University of New Mexico Health Sciences Center

Albuquerque, New Mexico, United States

Site Status

Winthrop University Hospital

Mineola, New York, United States

Site Status

NYU Langone Medical Center

New York, New York, United States

Site Status

University of Rochester - University of Rochester Medical Center

Rochester, New York, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

The Lindner Clinical Trial Center

Cincinnati, Ohio, United States

Site Status

University of Cincinnati - Department of Internal Medicine Pulmonary, Critical Care & Sleep Medicine

Cincinnati, Ohio, United States

Site Status

Cleveland Clinic

Cleveland, Ohio, United States

Site Status

The Ohio State University Wexner Medical Center

Columbus, Ohio, United States

Site Status

Oklahoma Heart Hospital

Oklahoma City, Oklahoma, United States

Site Status

Oregon Health & Science University

Portland, Oregon, United States

Site Status

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

University of Texas Southwestern Medical Center

Dallas, Texas, United States

Site Status

The Methodist Hospital Research Institute

Houston, Texas, United States

Site Status

The University of Texas - Health Science Center & Medical School at Houston

Houston, Texas, United States

Site Status

University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics

Houston, Texas, United States

Site Status

University of Utah

Salt Lake City, Utah, United States

Site Status

Aurora Health Care

Milwaukee, Wisconsin, United States

Site Status

Centro Médico Dra de Salvo

Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina

Site Status

Instituto de Investigaciones Clínicas Mar Del Plata

Buenos Aires, Mar Del Plata, Argentina

Site Status

Instituto de Cardiologia de Corrientes Juana Francisca Cabral

Corrientes, , Argentina

Site Status

Hospital Privado Centro Médico de Córdoba

Córdoba, , Argentina

Site Status

Instituto Cardiovascular de Rosario

Rosario, , Argentina

Site Status

Hospital Provincial Dr Jose Maria Cullen

Santa Fe, , Argentina

Site Status

St Vincent's Hospital Sydney

Darlinghurst, New South Wales, Australia

Site Status

John Hunter Hospital

New Lambton, New South Wales, Australia

Site Status

Princess Alexandra Hospital

Brisbane, Queensland, Australia

Site Status

Royal Hobart Hospital

Hobart, Tasmania, Australia

Site Status

UZ Leuven

Leuven, Vlaams Brabant, Belgium

Site Status

Hospital Erasme

Brussels, , Belgium

Site Status

Irmandade Da Santa Casa de Misericordia de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Hospital Dia do Pulmão

Blumenau, Santa Catarina, Brazil

Site Status

Instituto do Coração - HCFMUSP

São Paulo, , Brazil

Site Status

Peter Lougheed Centre

Calgary, Alberta, Canada

Site Status

Vancouver General Hospital

Vancouver, British Columbia, Canada

Site Status

London Health Sciences Centre

London, Ontario, Canada

Site Status

Centre Hospitalier de l'Université Laval

Sainte-Foy, Quebec, Canada

Site Status

Vseobecna fakultni nemocnice v Praze

Prague, , Czechia

Site Status

Institut klinicke a experimentalni mediciny

Prague, , Czechia

Site Status

Universitatsklinkum Carl Gustav Carus an der Tu

Dresden, , Germany

Site Status

Universitatsklinikum Hamburg Eppendorf

Hamburg, , Germany

Site Status

Thorax Klinik

Heidelberg, , Germany

Site Status

Hadassah University Hospital Ein Kerem

Jerusalem, , Israel

Site Status

Rabin Medical Center

Petah Tikva, , Israel

Site Status

Nippon Medical School Hospital

Tokyo, Bunkyo-ku, Japan

Site Status

Kobe University Hospital

Kobe, Hyōgo, Japan

Site Status

Kitasato University Hospital

Sagamihara, Kanagawa, Japan

Site Status

Kyorin University Hospital

Tokyo, Mitaka-shi, Japan

Site Status

National Hospital Organization Okayama Medical Center

Okayama, Okayama-ken, Japan

Site Status

Chiba University Hospital

Chiba, , Japan

Site Status

Hokkaido University Hospital

Sapporo, , Japan

Site Status

Kurume University Medical Center

Sendai, , Japan

Site Status

National Cerebral and Cardiovascular Center

Suita, , Japan

Site Status

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Mexico City, Mexico City, Mexico

Site Status

Instituto Nacional de Cardiologia Dr. Ignacio Chavez

Mexico City, Mexico City, Mexico

Site Status

Hospital Universitario Dr. Jose Eleuterio Gonzalez

Nuevo León, Monterrey, Mexico

Site Status

Unidad de Investigación Clínica En Medicina SC

Monterrey, Nuevo León, Mexico

Site Status

Vrije Universiteit Amsterdam

Amsterdam, North Holland, Netherlands

Site Status

Philippine Heart Center

Quezon City, National Capital Region, Philippines

Site Status

Makati Medical Center

Makati, , Philippines

Site Status

Philippine General Hospital (PGH)

Manila, , Philippines

Site Status

Hospital Universitario Marques de Valdecilla

Santander, Cantabria, Spain

Site Status

Hospital Universitario Vall d'Hebron

Barcelona, , Spain

Site Status

Hospital Universitario 12 de Octubre

Madrid, , Spain

Site Status

Hospital Universitario Puerta de Hierro

Majadahonda, , Spain

Site Status

Hospital Virgen de La Salud

Toledo, , Spain

Site Status

Golden Jubilee National Hospital

Glasgow, , United Kingdom

Site Status

Royal Free Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Belgium Brazil Canada Czechia Germany Israel Japan Mexico Netherlands Philippines Spain United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol: US Protocol

View Document

Document Type: Study Protocol: Japan Protocol

View Document

Document Type: Study Protocol: UK Protocol

View Document

Document Type: Study Protocol: Germany Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RTA 402-C-1602

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.